Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Income: 2021-2024

Historic Net Income for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$301.4 million.

  • Amylyx Pharmaceuticals' Net Income rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.9 million, marking a year-over-year increase of 42.66%. This contributed to the annual value of -$301.4 million for FY2024, which is 714.44% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Net Income is -$301.4 million, which was down 714.44% from $49.0 million recorded in FY2023.
  • Amylyx Pharmaceuticals' 5-year Net Income high stood at $49.0 million for FY2023, and its period low was -$301.4 million during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Net Income had a median value of -$199.5 million in 2022 and averaged -$150.6 million.
  • Its Net Income has fluctuated over the past 5 years, first spiked by 124.59% in 2023, then slumped by 714.44% in 2024.
  • Amylyx Pharmaceuticals' Net Income (Yearly) stood at -$87.9 million in 2021, then tumbled by 126.86% to -$199.5 million in 2022, then spiked by 124.59% to $49.0 million in 2023, then crashed by 714.44% to -$301.4 million in 2024.